Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused ...

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and ...

A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...

Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.

CINCINNATI (WKRC) - Some newer medications and light therapies may help people with a condition that causes a rash or irritation in the skin. Dermatitis is one of the most common skin conditions.

If none of your atopic dermatitis treatments have worked, you may be experiencing burnout (or treatment fatigue). Here's what ...

Add Yahoo as a preferred source to see more of our stories on Google. It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes ...

Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...

Numerous cases involving different types of peristomal skin dermatitis have been documented in the literature. Stevenson described seven patients who presented with peristomal rashes. [10] Three of ...

Occupational contact dermatitis affects North American healthcare workers and is commonly linked to glove rubber accelerators, surfactants, and preservatives, a retrospective study finds.

Dry, flaky skin around the nose is common due to fewer oil glands and environmental factors like cold weather, low humidity, and harsh skincare products.

Nobody wants to return to a hot, stuffy house after a long day outside in the summer. However, you may think twice about ...